



Ross MacDonald, MD
Chief Medical Officer/ASVP
Correctional Health Services
55 Water Street, 18th Floor
New York, NY 10041
rmacdonald@nychhc.org
646-614-0075

June 27, 2018

Martha W. King
Executive Director
NYC Board of Correction
1 Centre Street, Room 2213
New York, NY 10007

Dear Ms. King:

In accordance with the Board of Correction's New York City Correctional Health Care Minimum Standards, Section 3-13, "Variances," the Correctional Health Services (CHS) division of the NYC Health + Hospitals requests renewal, for a 6-month period, of a continuing variance from Section 3-04(b)(2)(v)(a) of the Minimum Standards, which requires that a tuberculin skin test (TST) be administered during the intake screening process for inmates who do not have a prior history of a positive reaction to the test. The variance, first granted by the Board in July 2013, and applicable to inmates throughout the NYC correctional system, authorizes CHS to use either interferon gamma release assays (IGRA) or TST for tuberculosis screening, and to exempt from repeat screening those prisoners who have a documented negative test in the six months prior to their admission.

The new tuberculosis screening program began at the RMSC in 2011 and then at facilities housing male inmates in 2012. Since implementation of the program, we have observed that the use of IGRAs at intake is feasible and adds negligible additional time to the intake process, while saving significant time subsequently by obviating the need for post-intake follow-up of TST results and associated documentation. CHS has now had many years of experience with IGRA, which has proven to be a valuable and effective tool in controlling tuberculosis in the jail system.

Accompanying this letter is our report on the IGRA initiative as required by the terms of the variance.

The consideration of the Board members and staff is greatly appreciated in this matter.

Sincerely,

A handwritten signature in black ink, appearing to be 'RM', written in a cursive style.

Ross MacDonald, MD
Correctional Health Services

cc: Patsy Yang, DrPH

QuantiFERON (QFT) Progress Report

December 1, 2017 - May 31, 2018

Discription	Male NYSIDs (12/1/2017 - 5/31/2018)	% Male	Female NYSIDs (12/1/2017 - 5/31/2018)	% Female	Total NYSIDs (12/1/2017 - 5/31/2018)	% Total
Total NYSIDs with Intakes or State Transfer w/ QFT Orders	16,406		1,677		18,083	
Ineligibles: (% of NYSIDs)						
State Transfers	112	0.7%	17	1.0%	129	0.7%
Positive History	810	4.9%	81	4.8%	891	4.9%
Patients had negative results in previous 6 months	808	4.9%	63	3.8%	871	4.8%
Total Ineligible Patients	1,730	10.5%	161	9.6%	1,891	10.5%
Not Tested (% of NYSIDs)						
Lab Result = "Test Not Performed"	18	0.1%	0	0.0%	18	0.1%
Lab Result = "Refused"	102	0.6%	10	0.6%	112	0.6%
Lab Result = "Not available/Discharged"	368	2.2%	51	3.0%	419	2.3%
Total Not Tested Patients	488	3.0%	61	3.6%	549	3.0%
Total Eligible Intakes or State Transfer w/ QFT Orders that were tested	14,188	86.5%	1,455	86.8%	15,643	86.5%
Lab Result Breakdown for Eligibles (% of Eligibles)						
Normal/Negative/Non-Reactive	13,680	96.4%	1,397	96.0%	15,077	96.4%
Abnormal/Positive/Reactive	414	2.9%	35	2.4%	449	2.9%
Indeterminate	94	0.7%	23	1.6%	117	0.7%